Exact Mass: 309.20925320000003

Exact Mass Matches: 309.20925320000003

Found 217 metabolites which its exact mass value is equals to given mass value 309.20925320000003, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Methadone

GlaxoSmithKline brand OF methadone hydrochloride

C21H27NO (309.20925320000003)


A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of morphine. It also has a depressant action on the cough center and may be given to control intractable cough associated with terminal lung cancer. Methadone is also used as part of the treatment of dependence on opioid drugs, although prolonged use of methadone itself may result in dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3) CONFIDENCE standard compound; INTERNAL_ID 513; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8112; ORIGINAL_PRECURSOR_SCAN_NO 8110 CONFIDENCE standard compound; INTERNAL_ID 513; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8059; ORIGINAL_PRECURSOR_SCAN_NO 8057 CONFIDENCE standard compound; INTERNAL_ID 513; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8114; ORIGINAL_PRECURSOR_SCAN_NO 8112 CONFIDENCE standard compound; INTERNAL_ID 513; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8021; ORIGINAL_PRECURSOR_SCAN_NO 8016 CONFIDENCE standard compound; INTERNAL_ID 513; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8067; ORIGINAL_PRECURSOR_SCAN_NO 8064 CONFIDENCE standard compound; INTERNAL_ID 513; DATASET 20200303_ENTACT_RP_MIX506; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8100; ORIGINAL_PRECURSOR_SCAN_NO 8098 N - Nervous system > N07 - Other nervous system drugs > N07B - Drugs used in addictive disorders > N07BC - Drugs used in opioid dependence D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D019141 - Respiratory System Agents > D000996 - Antitussive Agents D002491 - Central Nervous System Agents > D000700 - Analgesics CONFIDENCE standard compound; EAWAG_UCHEM_ID 2828 CONFIDENCE standard compound; INTERNAL_ID 1628

   

Fluperlapine

6-fluoro-10-(4-methylpiperazin-1-yl)-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3(8),4,6,9,11,13-heptaene

C19H20FN3 (309.1641172)


D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist

   

Diphenidol

SmithKline beecham brand OF diphenidol hydrochloride

C21H27NO (309.20925320000003)


Diphenidol is only found in individuals that have used or taken this drug. It is an antiemetic agent used in the treatment of vomiting and vertigo. Diphenidol overdose may result in serious toxicity in children.The mechanism by which diphenidol exerts its antiemetic and antivertigo effects is not precisely known. It is thought to diminish vestibular stimulation and depress labyrinthine function and as an antimuscarinic agent. An action on the medullary chemoreceptive trigger zone may also be involved in the antiemetic effect. Diphenidol has no significant sedative, tranquilizing, or antihistaminic action. It has a weak peripheral anticholinergic effect. D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics D002491 - Central Nervous System Agents

   

Metipranolol

Acetic acid 4-(2-hydroxy-3-isopropylamino-propoxy)-2,3,6-trimethyl-phenyl ester

C17H27NO4 (309.1939982)


Metipranolol is only found in individuals that have used or taken this drug. It is a beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent. [PubChem]Although it is known that metipranolol binds the beta1 and beta2 adrenergic receptors, the mechanism of metipranolols action is not known. It has no significant intrinsic sympathomimetic activity, and has only weak local anesthetic (membrane-stabilizing) and myocardial depressant activity. It appears that the ophthalmic beta-adrenergic blocking agents reduce aqueous humor production, as demonstrated by tonography and fluorophotometry. A slight increase in aqueous humor outflow may be an additional mechanism. S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01ED - Beta blocking agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents Metipranolol is a nonselective and orally active β-adrenergic receptor antagonist. Metipranolol can be used for hypertension and glaucoma research[1][2].

   

Palustrine

(13S,17S)-17-[(1S)-1-hydroxypropyl]-1,5,10-triazabicyclo[11.4.0]heptadec-14-en-11-one

C17H31N3O2 (309.2416146)


   

ISOPROPALIN

ISOPROPALIN

C15H23N3O4 (309.1688478)


CONFIDENCE standard compound; INTERNAL_ID 1344; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10647; ORIGINAL_PRECURSOR_SCAN_NO 10642 CONFIDENCE standard compound; INTERNAL_ID 1344; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10600; ORIGINAL_PRECURSOR_SCAN_NO 10598 CONFIDENCE standard compound; INTERNAL_ID 1344; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10624; ORIGINAL_PRECURSOR_SCAN_NO 10622 CONFIDENCE standard compound; INTERNAL_ID 1344; DATASET 20200303_ENTACT_RP_MIX508; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10736; ORIGINAL_PRECURSOR_SCAN_NO 10734 CONFIDENCE standard compound; INTERNAL_ID 1344; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 10608; ORIGINAL_PRECURSOR_SCAN_NO 10605

   

Pro-Pro-Pro

Pro-Pro-Pro

C15H23N3O4 (309.1688478)


A tripeptide composed of three L-proline units joined by peptide linkages.

   

Nadolol

Nadolol

C17H27NO4 (309.1939982)


C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AA - Beta blocking agents, non-selective C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents CONFIDENCE standard compound; EAWAG_UCHEM_ID 3072 Nadolol (SQ-11725) is a non-selective and orally active β-adrenergic receptors blocker and is a substrate of organic anion transporting polypeptide 1A2 (OATP1A2). Nadolol has the the potential for high blood pressure, angina pectoris and vascular headaches research[1][2][3].

   

RO1138452

N-[4-[(4-Propan-2-yloxyphenyl)methyl]phenyl]-4,5-dihydro-1H-imidazol-2-amine

C19H23N3O (309.1841028)


   

Atherosperminine

2-(3,4-Dimethoxyphenanthren-1-yl)-N,N-dimethylethan-1-amine

C20H23NO2 (309.1728698)


Atherosperminine is an alkaloid. Atherosperminine is a natural product found in Cryptocarya angulata, Friesodielsia velutina, and other organisms with data available. Atherosperminine is found in fruits. Atherosperminine is an alkaloid from the stem bark of Annona muricata (soursop

   

Nadolol

(2R,3S)-5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol

C17H27NO4 (309.1939982)


Nadolol is only found in individuals that have used or taken this drug. It is a non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for migraine disorders and for tremor. [PubChem]Like other beta-adrenergic antagonists, nadolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, nadolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. It also blocks beta-2 adrenergic receptors located in bronchiole smooth muscle, causing vasoconstriction. By binding beta-2 receptors in the juxtaglomerular apparatus, nadolol inhibits the production of renin, thereby inhibiting angiotensin II and aldosterone production. Nadolol therefore inhibits the vasoconstriction and water retention due to angiotensin II and aldosterone, respectively. C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AA - Beta blocking agents, non-selective C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents Nadolol (SQ-11725) is a non-selective and orally active β-adrenergic receptors blocker and is a substrate of organic anion transporting polypeptide 1A2 (OATP1A2). Nadolol has the the potential for high blood pressure, angina pectoris and vascular headaches research[1][2][3].

   

Zanthosimuline

2,6-dimethyl-2-(4-methylpent-3-en-1-yl)-2H,5H,6H-pyrano[3,2-c]quinolin-5-one

C20H23NO2 (309.1728698)


Zanthosimuline is found in fruits. Zanthosimuline is an alkaloid from root bark of Zanthoxylum simulans (Szechuan pepper). Alkaloid from root bark of Zanthoxylum simulans (Szechuan pepper). Zanthosimuline is found in herbs and spices and fruits.

   

Lysyltyrosine

(2S)-2-[(2S)-2,6-diaminohexanamido]-3-(4-hydroxyphenyl)propanoic acid

C15H23N3O4 (309.1688478)


Lysyltyrosine is a dipeptide composed of lysine and tyrosine. It is an incomplete breakdown product of protein digestion or protein catabolism. Dipeptides are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. Some dipeptides are known to have physiological or cell-signalling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis.

   

Tyrosyl-Lysine

6-Amino-2-{[2-amino-1-hydroxy-3-(4-hydroxyphenyl)propylidene]amino}hexanoate

C15H23N3O4 (309.1688478)


Tyrosyl-Lysine is a dipeptide composed of tyrosine and lysine. It is an incomplete breakdown product of protein digestion or protein catabolism. Some dipeptides are known to have physiological or cell-signaling effects although most are simply short-lived intermediates on their way to specific amino acid degradation pathways following further proteolysis. This dipeptide has not yet been identified in human tissues or biofluids and so it is classified as an Expected metabolite.

   

(2E,5Z,7E)-Decatrienoylcarnitine

3-[(2E,5Z,7E)-Deca-2,5,7-trienoyloxy]-4-(trimethylammonio)butanoic acid

C17H27NO4 (309.1939982)


(2E,5Z,7E)-Decatrienoylcarnitine is an acylcarnitine. More specifically, it is an (2E,5Z,7E)-decatrienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,5Z,7E)-Decatrienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2E,5Z,7E)-Decatrienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2Z,4E,6Z)-Decatrienoylcarnitine

3-(deca-2,4,6-trienoyloxy)-4-(trimethylazaniumyl)butanoate

C17H27NO4 (309.1939982)


(2Z,4E,6Z)-Decatrienoylcarnitine is an acylcarnitine. More specifically, it is an (2Z,4E,6Z)-deca-2,4,6-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2Z,4E,6Z)-Decatrienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2Z,4E,6Z)-Decatrienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(3Z,5E,7E)-Decatrienoylcarnitine

3-(deca-3,5,7-trienoyloxy)-4-(trimethylazaniumyl)butanoate

C17H27NO4 (309.1939982)


(3Z,5E,7E)-Decatrienoylcarnitine is an acylcarnitine. More specifically, it is an (3Z,5E,7E)-deca-3,5,7-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (3Z,5E,7E)-Decatrienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (3Z,5E,7E)-Decatrienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2E,6E,8E)-Decatrienoylcarnitine

3-(deca-2,6,8-trienoyloxy)-4-(trimethylazaniumyl)butanoate

C17H27NO4 (309.1939982)


(2E,6E,8E)-Decatrienoylcarnitine is an acylcarnitine. More specifically, it is an (2E,6E,8E)-deca-2,6,8-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,6E,8E)-Decatrienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2E,6E,8E)-Decatrienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2E,4E,7E)-Decatrienoylcarnitine

3-(deca-2,4,7-trienoyloxy)-4-(trimethylazaniumyl)butanoate

C17H27NO4 (309.1939982)


(2E,4E,7E)-Decatrienoylcarnitine is an acylcarnitine. More specifically, it is an (2E,4E,7E)-deca-2,4,7-trienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,4E,7E)-Decatrienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2E,4E,7E)-Decatrienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-(Diphenylmethoxymethyl)-1-ethylpiperidine hydrochloride

3-(Diphenylmethoxymethyl)-1-ethylpiperidine hydrochloride

C21H27NO (309.20925320000003)


   

N-Demethyllysergic acid diethylamide

N,N-diethyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide

C19H23N3O (309.1841028)


   

4-Diphenylacetoxy-n-methylpiperidine

1-Methylpiperidin-4-yl diphenylacetic acid

C20H23NO2 (309.1728698)


   

Solgol

5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol

C17H27NO4 (309.1939982)


D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents Nadolol (SQ-11725) is a non-selective and orally active β-adrenergic receptors blocker and is a substrate of organic anion transporting polypeptide 1A2 (OATP1A2). Nadolol has the the potential for high blood pressure, angina pectoris and vascular headaches research[1][2][3].

   

Lonol

N,N-Dimethyl-3-[[1-(phenylmethyl)-3-indazolyl]oxy]-1-propanamine

C19H23N3O (309.1841028)


M - Musculo-skeletal system > M02 - Topical products for joint and muscular pain > M02A - Topical products for joint and muscular pain > M02AA - Antiinflammatory preparations, non-steroids for topical use G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02C - Other gynecologicals > G02CC - Antiinflammatory products for vaginal administration M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids A - Alimentary tract and metabolism > A01 - Stomatological preparations > A01A - Stomatological preparations C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic R - Respiratory system > R02 - Throat preparations > R02A - Throat preparations D000893 - Anti-Inflammatory Agents

   

Dexoxadrol

2-(2,2-Diphenyl-1,3-dioxolan-4-yl)piperidine

C20H23NO2 (309.1728698)


   

Gevotroline

8-Fluoro-2,3,4,5-tetrahydro-2-[3-(3-pyridinyl)propyl]1H-pyrido[4,3-b]indole

C19H20FN3 (309.1641172)


C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent

   

Palustrine

13-(1-hydroxypropyl)-1H,2H,3H,4H,5H,6H,7H,8H,9H,10H,11H,13H,14H,16aH-pyrido[2,1-d]1,5,9-triazacyclotridecan-2-one

C17H31N3O2 (309.2416146)


   

Pro-Pro-Pro

1-[1-(pyrrolidine-2-carbonyl)pyrrolidine-2-carbonyl]pyrrolidine-2-carboxylic acid

C15H23N3O4 (309.1688478)


   

N-[4-[(4-Propan-2-yloxyphenyl)methyl]phenyl]-4,5-dihydro-1H-imidazol-2-amine

N-(4-{[4-(propan-2-yloxy)phenyl]methyl}phenyl)-4,5-dihydro-1H-imidazol-2-amine

C19H23N3O (309.1841028)


   

(9Z,11E,14Z)-(13S)-hydroperoxyoctadeca-(9,11,14)-trienoate

(9Z,11E,14Z)-(13S)-Hydroperoxyoctadeca-(9,11,14)-trienoic acid

C18H29O4 (309.2065734)


(9z,11e,14z)-(13s)-hydroperoxyoctadeca-(9,11,14)-trienoate is practically insoluble (in water) and a weakly acidic compound (based on its pKa). (9z,11e,14z)-(13s)-hydroperoxyoctadeca-(9,11,14)-trienoate can be found in a number of food items such as wasabi, european chestnut, savoy cabbage, and prunus (cherry, plum), which makes (9z,11e,14z)-(13s)-hydroperoxyoctadeca-(9,11,14)-trienoate a potential biomarker for the consumption of these food products.

   
   
   
   
   
   
   

CJ 13217

(E)-2-(3,7-Dimethyl-2,6-octadienyl)-1,3-dimethyl-4(1H)-quinolinone

C21H27NO (309.20925320000003)


   

6-Norlysergic acid diethylamide

6-Norlysergic acid diethylamide

C19H23N3O (309.1841028)


   

BENZYDAMINE

BENZYDAMINE

C19H23N3O (309.1841028)


M - Musculo-skeletal system > M02 - Topical products for joint and muscular pain > M02A - Topical products for joint and muscular pain > M02AA - Antiinflammatory preparations, non-steroids for topical use G - Genito urinary system and sex hormones > G02 - Other gynecologicals > G02C - Other gynecologicals > G02CC - Antiinflammatory products for vaginal administration M - Musculo-skeletal system > M01 - Antiinflammatory and antirheumatic products > M01A - Antiinflammatory and antirheumatic products, non-steroids A - Alimentary tract and metabolism > A01 - Stomatological preparations > A01A - Stomatological preparations C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic R - Respiratory system > R02 - Throat preparations > R02A - Throat preparations D000893 - Anti-Inflammatory Agents

   

Benproperine

Benproperine

C21H27NO (309.20925320000003)


R - Respiratory system > R05 - Cough and cold preparations > R05D - Cough suppressants, excl. combinations with expectorants C78273 - Agent Affecting Respiratory System > C66917 - Antitussive Agent CONFIDENCE standard compound; EAWAG_UCHEM_ID 3296

   
   

2-[(1-Benzyl-4-piperidyl)amino]-6-fluorobenzonitrile

2-[(1-Benzyl-4-piperidyl)amino]-6-fluorobenzonitrile

C19H20FN3 (309.1641172)


   
   

Dihydoroferuloyl Octylamine

Dihydoroferuloyl Octylamine

C18H31NO3 (309.2303816)


Annotation level-3

   

(16aR)-13t-((S)-1-Hydroxy-propyl)-(16ar)-1,4,5,6,7,8,9,10,11,13,16,16a-dodecahydro-3H-pyrido[2,1-d][1,5,9]triazacyclotridecin-2-on|4-(1-hydroxy-propyl)-1,4,6,7,8,9,10,11,12,13,15,15a-dodecahydro-5H-4a,8,13-triaza-benzocyclotridecen-14-one|Palustrin|Palustrine

(16aR)-13t-((S)-1-Hydroxy-propyl)-(16ar)-1,4,5,6,7,8,9,10,11,13,16,16a-dodecahydro-3H-pyrido[2,1-d][1,5,9]triazacyclotridecin-2-on|4-(1-hydroxy-propyl)-1,4,6,7,8,9,10,11,12,13,15,15a-dodecahydro-5H-4a,8,13-triaza-benzocyclotridecen-14-one|Palustrin|Palustrine

C17H31N3O2 (309.2416146)


   

17alpha-cyanomethyl-1,3,5(10),9(11)-estratetraene-3,17-diol|17alpha-Cyanomethylestra-1,3,5(10),9(11)-tetraen-3,17beta-diol|J 1201

17alpha-cyanomethyl-1,3,5(10),9(11)-estratetraene-3,17-diol|17alpha-Cyanomethylestra-1,3,5(10),9(11)-tetraen-3,17beta-diol|J 1201

C20H23NO2 (309.1728698)


   
   
   

dechlorofontomide|Dechlorofontonamide

dechlorofontomide|Dechlorofontonamide

C20H23NO2 (309.1728698)


   
   

2-methyl-3-butylprodiginine|4-(n-butyl)prodigiosin|n4PG

2-methyl-3-butylprodiginine|4-(n-butyl)prodigiosin|n4PG

C19H23N3O (309.1841028)


   
   
   

12-hydroxy-7-multijuguinol

12-hydroxy-7-multijuguinol

C18H31NO3 (309.2303816)


   
   

1-methyl-2-[(1E,5Z)-1,5-undecadienyl]-4(1H)-quinolone

1-methyl-2-[(1E,5Z)-1,5-undecadienyl]-4(1H)-quinolone

C21H27NO (309.20925320000003)


   

12-hydroxy-8-multijuguinol

12-hydroxy-8-multijuguinol

C18H31NO3 (309.2303816)


   

N,3-Di-Ac-2-Amino-5,7-tetradecadien-3-ol

N,3-Di-Ac-2-Amino-5,7-tetradecadien-3-ol

C18H31NO3 (309.2303816)


   
   

hydroxylanyuamide I

hydroxylanyuamide I

C18H31NO3 (309.2303816)


   
   

N1,N10-ditigloylspermidine

N1,N10-ditigloylspermidine

C17H31N3O2 (309.2416146)


   

pseudopteroxazole

pseudopteroxazole

C21H27NO (309.20925320000003)


A natural product found in Pseudopterogorgia elisabethae.

   

2,3,3,4-Tetrahydro-Mantella Alkalod 241F

2,3,3,4-Tetrahydro-Mantella Alkalod 241F

C17H27NO4 (309.1939982)


   

4-(3-Methyl-but-2-ene)oxy, N-benzoyl phenethyl amine

4-(3-Methyl-but-2-ene)oxy, N-benzoyl phenethyl amine

C20H23NO2 (309.1728698)


   

N-cis-tetradec-9Z-enoyl-L-Homoserine lactone

N-cis-tetradec-9Z-enoyl-L-Homoserine lactone

C18H31NO3 (309.2303816)


   
   

FLUPERLAPINE

FLUPERLAPINE

C19H20FN3 (309.1641172)


D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist

   

methadone

methadone

C21H27NO (309.20925320000003)


N - Nervous system > N07 - Other nervous system drugs > N07B - Drugs used in addictive disorders > N07BC - Drugs used in opioid dependence D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D019141 - Respiratory System Agents > D000996 - Antitussive Agents D002491 - Central Nervous System Agents > D000700 - Analgesics

   
   

Cypridinid etioluciferin

Cypridinid etioluciferin

C16H19N7 (309.1701854)


   

Macusine B

Macusine B

[C20H25N2O]+ (309.19667799999996)


Origin: Plant; SubCategory_DNP: Monoterpenoid indole alkaloids, Bisindole alkaloids, Indole alkaloids

   

Brevicarine, N-Ac

Brevicarine, N-Ac

C19H23N3O (309.1841028)


Origin: Plant; SubCategory_DNP: Alkaloids derived from tryptophan, beta-Carboline alkaloids, Indole alkaloids

   
   
   
   

CAY10441

4,5-dihydro-N-[4-[[4-(1-methylethoxy)phenyl]methyl]phenyl]-1H-imadazol-2-amine

C19H23N3O (309.1841028)


   

C14:1-9-cis-(L)-HSL

(S,Z)-N-(2-oxotetrahydrofuran-3-yl)tetradec-9-enamide

C18H31NO3 (309.2303816)


   

Lys-tyr

6-amino-2-[2-amino-3-(4-hydroxyphenyl)propanamido]hexanoic acid

C15H23N3O4 (309.1688478)


A dipeptide formed from L-lysine and L-tyrosine residues.

   

Tyr-lys

2-(2,6-diaminohexanamido)-3-(4-hydroxyphenyl)propanoic acid

C15H23N3O4 (309.1688478)


A dipeptide formed from L-tyrosine and L-lysine residues.

   

atherospermine

3,4-Dimethoxy-N,N-dimethyl-1-phenanthreneethanamine, 9CI

C20H23NO2 (309.1728698)


   

Zanthosimuline

2,6-dimethyl-2-(4-methylpent-3-en-1-yl)-2H,5H,6H-pyrano[3,2-c]quinolin-5-one

C20H23NO2 (309.1728698)


   

CAR 10:3

(2E,5Z,7E)-deca-2,5,7-trienoylcarnitine;2-trans,5-cis,7-trans-decatrienoylcarnitine;3-[(2E,5Z,7E)-deca-2,5,7-trienoyloxy]-4-(trimethylammonio)butanoate

C17H27NO4 (309.1939982)


   
   

N-(7Z-tetradecenoyl)-homoserine lactone

N-(7Z-tetradecenoyl)-homoserine lactone

C18H31NO3 (309.2303816)


   

2-ethylhexyl prop-2-enoate,prop-2-enenitrile,prop-2-enoic acid

2-ethylhexyl prop-2-enoate,prop-2-enenitrile,prop-2-enoic acid

C17H27NO4 (309.1939982)


   

Amolanone

Amolanone

C20H23NO2 (309.1728698)


C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent

   
   
   

Isomethadone

6-(Dimethylamino)-5-methyl-4,4-diphenyl-3-hexanone

C21H27NO (309.20925320000003)


C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist

   

4-[trans-4-(trans-4-Propylcyclohexyl) cyclohexyl]benzonitrile

4-[trans-4-(trans-4-Propylcyclohexyl) cyclohexyl]benzonitrile

C22H31N (309.2456366)


   

N-Boc-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester

N-Boc-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester

C16H28BNO4 (309.21112780000004)


   

2-(N-Propyl-N-phenethylamino)-5-hydroxytetralin

2-(N-Propyl-N-phenethylamino)-5-hydroxytetralin

C21H27NO (309.20925320000003)


D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists

   

N-(2,5-dimethylphenyl)-2-[4-(2-methylpropyl)phenyl]propanamide

N-(2,5-dimethylphenyl)-2-[4-(2-methylpropyl)phenyl]propanamide

C21H27NO (309.20925320000003)


   

4-(N-PHENYLAMINOMETHYL)PHENYLBORONIC ACID

4-(N-PHENYLAMINOMETHYL)PHENYLBORONIC ACID

C19H24BNO2 (309.1899994)


   

2,4,6-Triphenyl-1,3,5,2,4,6-triazatriborinane

2,4,6-Triphenyl-1,3,5,2,4,6-triazatriborinane

C18H18B3N3 (309.1779798)


   

3-[(3,4-dimethylphenyl)methyl]-7,7-dimethyl-6,8-dihydro-1H-quinoline-2,5-dione

3-[(3,4-dimethylphenyl)methyl]-7,7-dimethyl-6,8-dihydro-1H-quinoline-2,5-dione

C20H23NO2 (309.1728698)


   

Carbamic acid, N,N-3,5-pyridinediylbis-, C,C-bis(1,1-dimethylethyl) ester

Carbamic acid, N,N-3,5-pyridinediylbis-, C,C-bis(1,1-dimethylethyl) ester

C15H23N3O4 (309.1688478)


   

ethyl anthranilate / cuminaldehyde schiffs base

ethyl anthranilate / cuminaldehyde schiffs base

C20H23NO2 (309.1728698)


   

2-(4-tert-butoxycarbonylamino-butylamino)-nicotinic acid

2-(4-tert-butoxycarbonylamino-butylamino)-nicotinic acid

C15H23N3O4 (309.1688478)


   

2-(methylamino)pyridin-3-yl)methyl 2-((tert-butoxycarbonyl)(methyl)amino)acetate

2-(methylamino)pyridin-3-yl)methyl 2-((tert-butoxycarbonyl)(methyl)amino)acetate

C15H23N3O4 (309.1688478)


   

N,N-DIMETHYL-N-[3-(SULFOOXY)PROPYL]-1-NONANAMINIUM HYDROXIDE, INNER SALT

N,N-DIMETHYL-N-[3-(SULFOOXY)PROPYL]-1-NONANAMINIUM HYDROXIDE, INNER SALT

C14H31NO4S (309.1973686)


   

5-tert-butyl 3-ethyl 1-methyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-3,5(4H)-dicarboxylate

5-tert-butyl 3-ethyl 1-methyl-6,7-dihydro-1H-pyrazolo[4,3-c]pyridine-3,5(4H)-dicarboxylate

C15H23N3O4 (309.1688478)


   

acetic acid,tert-butyl N-(5,6,7,8-tetrahydro-1,7-naphthyridin-3-yl)carbamate

acetic acid,tert-butyl N-(5,6,7,8-tetrahydro-1,7-naphthyridin-3-yl)carbamate

C15H23N3O4 (309.1688478)


   

6-methylheptyl prop-2-enoate,prop-2-enenitrile,prop-2-enoic acid

6-methylheptyl prop-2-enoate,prop-2-enenitrile,prop-2-enoic acid

C17H27NO4 (309.1939982)


   

bis(2-hydroxyethyl)-3-aminopropyltriethoxysilane

bis(2-hydroxyethyl)-3-aminopropyltriethoxysilane

C13H31NO5Si (309.19713959999996)


   

4-Anilino-1-benzylpiperidine-4-carboxamide

4-Anilino-1-benzylpiperidine-4-carboxamide

C19H23N3O (309.1841028)


   

bis(3,5-dimethylphenyl)-[(2R)-pyrrolidin-2-yl]methanol

bis(3,5-dimethylphenyl)-[(2R)-pyrrolidin-2-yl]methanol

C21H27NO (309.20925320000003)


   

4-(2-PIPERIDYLETHOXY)BENZOPHENONE

4-(2-PIPERIDYLETHOXY)BENZOPHENONE

C20H23NO2 (309.1728698)


   

di-tert-butyl 2 6-dimethyl-1 4-dihydrop&

di-tert-butyl 2 6-dimethyl-1 4-dihydrop&

C17H27NO4 (309.1939982)


   

6-methyl-N1-(3-methyl-1-(6-(methylamino)pyrimidin-4-yl)-1H-pyrazol-5-yl)benzene-1,3-diamine

6-methyl-N1-(3-methyl-1-(6-(methylamino)pyrimidin-4-yl)-1H-pyrazol-5-yl)benzene-1,3-diamine

C16H19N7 (309.1701854)


   

Sodium N-dodecanoyl-L-serinate

Sodium N-dodecanoyl-L-serinate

C15H28NNaO4 (309.1915928)


   
   

Levomethadone

(6R)-6-(dimethylamino)-4,4-diphenylheptan-3-one

C21H27NO (309.20925320000003)


N - Nervous system > N07 - Other nervous system drugs > N07B - Drugs used in addictive disorders > N07BC - Drugs used in opioid dependence C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist

   

(1-Ethyl-3-pyrrolidinyl)(diphenyl)acetic acid

(1-Ethyl-3-pyrrolidinyl)(diphenyl)acetic acid

C20H23NO2 (309.1728698)


   

3-pyridin-3-yl-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridazine

3-pyridin-3-yl-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridazine

C18H23N5 (309.1953358)


   

3-pyridin-4-yl-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridazine

3-pyridin-4-yl-6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridazine

C18H23N5 (309.1953358)


   

[4-[2-(4-cyclopropylpiperazin-1-yl)pyrimidin-5-yl]phenyl]methanamine

[4-[2-(4-cyclopropylpiperazin-1-yl)pyrimidin-5-yl]phenyl]methanamine

C18H23N5 (309.1953358)


   

TERT-BUTYL 5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3,6-DIHYDROPYRIDINE-1(2H)-CARBOXYLATE

TERT-BUTYL 5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3,6-DIHYDROPYRIDINE-1(2H)-CARBOXYLATE

C16H28BNO4 (309.21112780000004)


   

Dioxadrol

(2S)-2-[(4S)-2,2-Diphenyl-1,3-dioxolan-4-yl]piperidine

C20H23NO2 (309.1728698)


D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics

   

bis(3,5-dimethylphenyl)-[(2S)-pyrrolidin-2-yl]methanol

bis(3,5-dimethylphenyl)-[(2S)-pyrrolidin-2-yl]methanol

C21H27NO (309.20925320000003)


   

A-412997 Dihydrochloride

A-412997 Dihydrochloride

C19H23N3O (309.1841028)


   

N-Boc-L-Adamantylglycine

N-Boc-L-Adamantylglycine

C17H27NO4 (309.1939982)


   

5-(4-butylphenyl)-N-cyclopentyl-2-methylpyrimidin-4-amine

5-(4-butylphenyl)-N-cyclopentyl-2-methylpyrimidin-4-amine

C20H27N3 (309.22048620000004)


   
   
   

N-[1-(2,3-Dihydro-1,4-benzodioxin-2-yl)ethylidene]-alpha-methylbenzenepropanamine

N-[1-(2,3-Dihydro-1,4-benzodioxin-2-yl)ethylidene]-alpha-methylbenzenepropanamine

C20H23NO2 (309.1728698)


   

9-[3-(dimethylamino)propyl]-10,10-dimethylanthracen-9-ol

9-[3-(dimethylamino)propyl]-10,10-dimethylanthracen-9-ol

C21H27NO (309.20925320000003)


   

Trans-Methyl 1-benzyl-4-p-tolylpyrrolidine-3-carboxylate

Trans-Methyl 1-benzyl-4-p-tolylpyrrolidine-3-carboxylate

C20H23NO2 (309.1728698)


   

2-(2-hex-1-ynylcyclohexyl)isoindole-1,3-dione

2-(2-hex-1-ynylcyclohexyl)isoindole-1,3-dione

C20H23NO2 (309.1728698)


   

1-(4-butoxyphenyl)-N-(4-butylphenyl)methanimine

1-(4-butoxyphenyl)-N-(4-butylphenyl)methanimine

C21H27NO (309.20925320000003)


   

3-((Phenylamino)methyl)phenylboronic acid, pinacol ester

3-((Phenylamino)methyl)phenylboronic acid, pinacol ester

C19H24BNO2 (309.1899994)


   
   

TERT-BUTYL 6-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3,4-DIHYDROPYRIDINE-1(2H)-CARBOXYLATE

TERT-BUTYL 6-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-3,4-DIHYDROPYRIDINE-1(2H)-CARBOXYLATE

C16H28BNO4 (309.21112780000004)


   

1-[3-(2-Methoxy-5-nitrophenoxy)propyl]-4-methylpiperazine

1-[3-(2-Methoxy-5-nitrophenoxy)propyl]-4-methylpiperazine

C15H23N3O4 (309.1688478)


   

4-(BENZYLOXY)-N-CYCLOHEXAMIDOANILINE

4-(BENZYLOXY)-N-CYCLOHEXAMIDOANILINE

C20H23NO2 (309.1728698)


   

3-(4-BOC-PIPERAZIN-1-YL-METHYL)-5-FLUOROANILINE

3-(4-BOC-PIPERAZIN-1-YL-METHYL)-5-FLUOROANILINE

C16H24FN3O2 (309.1852456)


   

Dextromethadone

Dextromethadone

C21H27NO (309.20925320000003)


D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D002491 - Central Nervous System Agents > D000700 - Analgesics

   

1-Tert-butyl-3-(2,5-dimethylbenzyl)-1H-pyrazolo[3,4-D]pyrimidin-4-amine

1-Tert-butyl-3-(2,5-dimethylbenzyl)-1H-pyrazolo[3,4-D]pyrimidin-4-amine

C18H23N5 (309.1953358)


   
   

2,3-Naphthalenediol, 5-((2R)-3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-, (2S,3R)-rel-

2,3-Naphthalenediol, 5-((2R)-3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-, (2S,3R)-rel-

C17H27NO4 (309.1939982)


   

2,3-Naphthalenediol, 5-((2R)-3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-, (2R,3S)-rel-

2,3-Naphthalenediol, 5-((2R)-3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)-1,2,3,4-tetrahydro-, (2R,3S)-rel-

C17H27NO4 (309.1939982)


   
   
   
   

1-[2-[3-(1-Methylethenyl)phenyl]propan-2-yl]-3-(4-methyl-2-pyridinyl)urea

1-[2-[3-(1-Methylethenyl)phenyl]propan-2-yl]-3-(4-methyl-2-pyridinyl)urea

C19H23N3O (309.1841028)


   

(S,Z)-N-(2-oxotetrahydrofuran-3-yl)tetradec-9-enamide

(S,Z)-N-(2-oxotetrahydrofuran-3-yl)tetradec-9-enamide

C18H31NO3 (309.2303816)


   
   

5-Deoxy-5-Piperidin-1-Ylthymidine

5-Deoxy-5-Piperidin-1-Ylthymidine

C15H23N3O4 (309.1688478)


   

(1S,4R,7AR)-4-Butoxy-1-[(1R)-1-formylpropyl]-2,4,5,6,7,7A-hexahydro-1H-isoindole-3-carboxylic acid

(1S,4R,7AR)-4-Butoxy-1-[(1R)-1-formylpropyl]-2,4,5,6,7,7A-hexahydro-1H-isoindole-3-carboxylic acid

C17H27NO4 (309.1939982)


   

N-methyl-N-[4-(1-methyl-9H-beta-carbolin-4-yl)butyl]acetamide

N-methyl-N-[4-(1-methyl-9H-beta-carbolin-4-yl)butyl]acetamide

C19H23N3O (309.1841028)


   

Fructosyllysine(1+)

Fructosyllysine(1+)

C12H25N2O7+ (309.16616799999997)


An amino-acid cation comprising fructosyllysine having a deprotonated carboxy group and both amino groups protonated; major species at pH 7.3.

   

(9Z,11E,13S,15Z)-13-Hydroperoxyoctadeca-9,11,15-trienoate

(9Z,11E,13S,15Z)-13-Hydroperoxyoctadeca-9,11,15-trienoate

C18H29O4- (309.2065734)


Conjugate base of (9Z,11E,13S,15Z)-13-hydroperoxyoctadeca-9,11,15-trienoic acid.

   

(9S,10E,12Z,15Z)-9-hydroperoxyoctadeca-10,12,15-trienoate

(9S,10E,12Z,15Z)-9-hydroperoxyoctadeca-10,12,15-trienoate

C18H29O4- (309.2065734)


   

Psicosyllysine(1+)

Psicosyllysine(1+)

C12H25N2O7+ (309.16616799999997)


An amino-acid cation comprising psicosyllysine having a deprotonated carboxy group and both amino groups protonated; major species at pH 7.3.

   

(9R,10E,12Z,15Z)-9-hydroperoxyoctadeca-10,12,15-trienoate

(9R,10E,12Z,15Z)-9-hydroperoxyoctadeca-10,12,15-trienoate

C18H29O4- (309.2065734)


   

(8E,10S,12Z,15Z)-10-hydroperoxyoctadec-8,12,15-trienoate

(8E,10S,12Z,15Z)-10-hydroperoxyoctadec-8,12,15-trienoate

C18H29O4- (309.2065734)


   

(2S)-3-methyl-2-[[2-[(1R,2R)-3-oxo-2-[(Z)-pent-2-enyl]cyclopentyl]acetyl]amino]butanoic acid

(2S)-3-methyl-2-[[2-[(1R,2R)-3-oxo-2-[(Z)-pent-2-enyl]cyclopentyl]acetyl]amino]butanoic acid

C17H27NO4 (309.1939982)


   

(9Z,11E,13S,14Z)-13-hydroperoxyoctadeca-9,11,14-trienoate

(9Z,11E,13S,14Z)-13-hydroperoxyoctadeca-9,11,14-trienoate

C18H29O4- (309.2065734)


The conjugate base of (9Z,11E,13S,14Z)-13-hydroperoxyoctadeca-9,11,14-trienic acid.

   
   
   

9-gamma-Ketol (linolenic acid)

9-gamma-Ketol (linolenic acid)

C18H29O4- (309.2065734)


   

9S-alpha-ketol (linolenic acid)

9S-alpha-ketol (linolenic acid)

C18H29O4- (309.2065734)


   

9(R)-alpha-ketol (linolenic acid)

9(R)-alpha-ketol (linolenic acid)

C18H29O4- (309.2065734)


   

(2S)-2-[[2-[(2Z)-2-Pentenyl]-3-oxocyclopentyl]acetylamino]-3-methylbutyric acid

(2S)-2-[[2-[(2Z)-2-Pentenyl]-3-oxocyclopentyl]acetylamino]-3-methylbutyric acid

C17H27NO4 (309.1939982)


   

(2Z,4E,6Z)-Decatrienoylcarnitine

(2Z,4E,6Z)-Decatrienoylcarnitine

C17H27NO4 (309.1939982)


   

(3Z,5E,7E)-Decatrienoylcarnitine

(3Z,5E,7E)-Decatrienoylcarnitine

C17H27NO4 (309.1939982)


   

(2E,6E,8E)-Decatrienoylcarnitine

(2E,6E,8E)-Decatrienoylcarnitine

C17H27NO4 (309.1939982)


   

(2E,4E,7E)-Decatrienoylcarnitine

(2E,4E,7E)-Decatrienoylcarnitine

C17H27NO4 (309.1939982)


   

(9E,11E,14E)-13-hydroperoxyoctadeca-9,11,14-trienoate

(9E,11E,14E)-13-hydroperoxyoctadeca-9,11,14-trienoate

C18H29O4- (309.2065734)


   
   

(9Z,11E,15Z)-13-hydroperoxyoctadecatrienoate

(9Z,11E,15Z)-13-hydroperoxyoctadecatrienoate

C18H29O4- (309.2065734)


   

4-[2-(1-hexyl-2-pyridin-1-iumyl)ethenyl]-N,N-dimethylaniline

4-[2-(1-hexyl-2-pyridin-1-iumyl)ethenyl]-N,N-dimethylaniline

C21H29N2+ (309.2330614)


   

(R)-2-hydroperoxy-alpha-linolenate

(R)-2-hydroperoxy-alpha-linolenate

C18H29O4- (309.2065734)


A hydroperoxy fatty acid anion that is the conjugate base of (R)-2-hydroperoxy-alpha-linolenic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

1-[4-[4-[(Phenylmethyl)amino]phenyl]-1-piperazinyl]ethanone

1-[4-[4-[(Phenylmethyl)amino]phenyl]-1-piperazinyl]ethanone

C19H23N3O (309.1841028)


   

(10E,12Z,15Z)-9-hydroperoxyoctadeca-10,12,15-trienoate

(10E,12Z,15Z)-9-hydroperoxyoctadeca-10,12,15-trienoate

C18H29O4- (309.2065734)


   

10-HPO(6,8,12)TrE(1-)

10-HPO(6,8,12)TrE(1-)

C18H29O4- (309.2065734)


A polyunsaturated fatty acid anion that is the conjugate base of 10-HPO(6,8,12)TrE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

10(R)-HPO(6,8,12)TrE(1-)

10(R)-HPO(6,8,12)TrE(1-)

C18H29O4- (309.2065734)


A polyunsaturated fatty acid anion that is the conjugate base of 10(R)-HPO(6,8,12)TrE, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

dihydro-ML-236C carboxylate

dihydro-ML-236C carboxylate

C18H29O4- (309.2065734)


   

(9Z,11E,13R,15Z)-13-hydroperoxyoctadecatrienoate

(9Z,11E,13R,15Z)-13-hydroperoxyoctadecatrienoate

C18H29O4- (309.2065734)


   

(9Z,11S,12Z,15Z)-11-hydroperoxyoctadecatrienoate

(9Z,11S,12Z,15Z)-11-hydroperoxyoctadecatrienoate

C18H29O4- (309.2065734)


   

5-Fluoro-2-[(3S)-1-(2-methylbenzyl)-3-pyrrolidinyl]-1H-benzimidazole

5-Fluoro-2-[(3S)-1-(2-methylbenzyl)-3-pyrrolidinyl]-1H-benzimidazole

C19H20FN3 (309.1641172)


   

(9Z,11R,12Z,15Z)-11-hydroperoxyoctadecatrienoate

(9Z,11R,12Z,15Z)-11-hydroperoxyoctadecatrienoate

C18H29O4- (309.2065734)


   
   

N-[2-(3-phenoxyphenoxy)ethyl]-N-prop-2-enyl-2-propen-1-amine

N-[2-(3-phenoxyphenoxy)ethyl]-N-prop-2-enyl-2-propen-1-amine

C20H23NO2 (309.1728698)


   

2-(4-tert-butylphenyl)-3-hydroxy-3-(1,3,4-trimethyl-1H-pyrazol-5-yl)acrylonitrile

2-(4-tert-butylphenyl)-3-hydroxy-3-(1,3,4-trimethyl-1H-pyrazol-5-yl)acrylonitrile

C19H23N3O (309.1841028)


   

N(2)-[(R)-2-amino-2-(4-hydroxyphenyl)acetyl]-N-butyl-L-serinamide

N(2)-[(R)-2-amino-2-(4-hydroxyphenyl)acetyl]-N-butyl-L-serinamide

C15H23N3O4 (309.1688478)


   
   
   
   
   

ketomycolate type-3 (XIII)

ketomycolate type-3 (XIII)

C18H29O4- (309.2065734)


   

5-oxo-18-hydroxy-(6E,8Z)-octadecadienoate

5-oxo-18-hydroxy-(6E,8Z)-octadecadienoate

C18H29O4- (309.2065734)


   

12,13-epoxy-(10R)-hydroxy-(8E,15Z)-octadecadienoate

12,13-epoxy-(10R)-hydroxy-(8E,15Z)-octadecadienoate

C18H29O4- (309.2065734)


   

N-Demethyllysergic acid diethylamide

N-Demethyllysergic acid diethylamide

C19H23N3O (309.1841028)


   

N-[(4E,8E,12E)-1,3-dihydroxypentadeca-4,8,12-trien-2-yl]propanamide

N-[(4E,8E,12E)-1,3-dihydroxypentadeca-4,8,12-trien-2-yl]propanamide

C18H31NO3 (309.2303816)


   

N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]butanamide

N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]butanamide

C18H31NO3 (309.2303816)


   

N-[(4E,8E,12E)-1,3-dihydroxyhexadeca-4,8,12-trien-2-yl]acetamide

N-[(4E,8E,12E)-1,3-dihydroxyhexadeca-4,8,12-trien-2-yl]acetamide

C18H31NO3 (309.2303816)


   

4-(3-(4-Trimethylsilyloxyphenoxy)propyl)morpholine

4-(3-(4-Trimethylsilyloxyphenoxy)propyl)morpholine

C16H27NO3Si (309.1760112)


   

2-Trimethylsilyloxy-N-(2-(diethylamino)ethyl)-3-pyridinecarboxamide

2-Trimethylsilyloxy-N-(2-(diethylamino)ethyl)-3-pyridinecarboxamide

C15H27N3O2Si (309.18724419999995)


   

4-(3-(4-(3-Hydroxybutoxy)phenoxy)propyl)morpholine

4-(3-(4-(3-Hydroxybutoxy)phenoxy)propyl)morpholine

C17H27NO4 (309.1939982)


   

2-(3-Hydroxybutoxy)-N-(2-(diethylamino)ethyl)-3-pyridinecarboxamide

2-(3-Hydroxybutoxy)-N-(2-(diethylamino)ethyl)-3-pyridinecarboxamide

C16H27N3O3 (309.20523119999996)


   

Metipranolol

Metipranolol

C17H27NO4 (309.1939982)


3-(Propan-2-ylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by a 4-acetoxy-2,3,5-trimethylphenoxy group. A non-cardioselective beta-blocker, it is used to lower intra-ocular pressure in the management of open-angle glaucoma. S - Sensory organs > S01 - Ophthalmologicals > S01E - Antiglaucoma preparations and miotics > S01ED - Beta blocking agents C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents Metipranolol is a nonselective and orally active β-adrenergic receptor antagonist. Metipranolol can be used for hypertension and glaucoma research[1][2].

   

Difenidol

DIPHENIDOL

C21H27NO (309.20925320000003)


D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents C78272 - Agent Affecting Nervous System > C267 - Antiemetic Agent D005765 - Gastrointestinal Agents > D000932 - Antiemetics D002491 - Central Nervous System Agents

   

Solgol

Nadolol

C17H27NO4 (309.1939982)


D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents Nadolol (SQ-11725) is a non-selective and orally active β-adrenergic receptors blocker and is a substrate of organic anion transporting polypeptide 1A2 (OATP1A2). Nadolol has the the potential for high blood pressure, angina pectoris and vascular headaches research[1][2][3].

   

Gevotroline

Gevotroline

C19H20FN3 (309.1641172)


C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent

   

4-Diphenylacetoxy-n-methylpiperidine

4-Diphenylacetoxy-n-methylpiperidine

C20H23NO2 (309.1728698)


   

(2E,5Z,7E)-decatrienoylcarnitine

(2E,5Z,7E)-decatrienoylcarnitine

C17H27NO4 (309.1939982)


An O-acylcarnitine having (2E,5Z,7E)-decatrienoyl as the acyl substituent.